Dr. Reddy's Laboratories Ltd. has announced the schedule for releasing its Q4 and full year FY26 financial results. The pharmaceutical company will unveil its financial performance for the quarter and year ended March 31, 2026, on Tuesday, May 12, 2026, following a Board Meeting.

Results Release Schedule

The company has outlined a comprehensive communication plan for the results announcement. The financial results will be released after the Board Meeting on May 12, 2026, and will be disseminated through multiple channels including stock exchanges, media outlets, the company website, and email communications.

Earnings Call Details

Following the results release, Dr. Reddy's management will conduct an earnings call to discuss the company's financial performance with investors and analysts. The call is scheduled for Tuesday, May 12, 2026, at 19:30 PM IST, which corresponds to 10:00 AM Eastern Time for international participants.

Interested stakeholders can pre-register for the earnings call through the company's dedicated webinar link. The management team will provide insights into the quarterly and annual performance, addressing key financial metrics and business developments during the period.

Additional Resources

Dr. Reddy's will ensure comprehensive access to the financial information by making the press meet presentation available on its website immediately after the results announcement. The company will also provide both audio recordings and complete transcripts of the earnings call on its website for those unable to participate in the live session.

The notification was signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR, and communicated to all relevant stock exchanges including NSE, BSE, NYSE, and NSE IFSC where the company's shares are listed.

Dr Reddy's Laboratories has achieved a significant regulatory milestone in Canada for its semaglutide injection, receiving Drug Identification Numbers on April 22, 2026. However, the pharmaceutical company continues to await final approval from Health Canada for market authorization of its diabetes medication.

Regulatory Progress Update

The receipt of Drug Identification Numbers represents a crucial step in the Canadian regulatory approval process for semaglutide injection. While this milestone indicates progress through Health Canada's review system, the company has clarified that final market approval is still pending.

Approval Process Context

Drug Identification Numbers are typically assigned during the later stages of the regulatory review process, indicating that Health Canada has progressed significantly in evaluating the semaglutide injection application. This development suggests the company has successfully navigated earlier regulatory requirements and documentation submissions.

Market Implications

Semaglutide represents a significant therapeutic advancement in diabetes treatment, and regulatory progress in major markets like Canada is closely monitored by healthcare stakeholders and investors. The assignment of Drug Identification Numbers demonstrates tangible progress toward potential market entry, though final approval timing remains subject to Health Canada's review completion.

Company Position

Dr Reddy's Laboratories continues to work collaboratively with Health Canada through the standard regulatory approval processes. The company's transparent communication regarding both the milestone achievement and pending approval status helps maintain accurate stakeholder expectations regarding the semaglutide timeline in the Canadian market.